Abstract:ABSTRACT Antibodies are frontline defenders against influenza virus infection, providing protection through multiple complementary mechanisms. Although a subset of monoclonal antibodies (mAbs) has been shown to restrict replication at the level of virus assembly and release, it remains unclear how potent and pervasive this mechanism of protection is, due in part to the challenge of separating this effect from other aspects of antibody function. To address this question, we developed imaging-based assays to determine how effectively a broad range of mAbs against the IAV surface proteins can specifically restrict viral egress. We find that classically neutralizing antibodies against hemagglutinin are broadly multifunctional, inhibiting virus assembly and release at concentrations 1–20-fold higher than the concentrations at which they inhibit viral entry. These antibodies are also capable of altering the morphological features of shed virions, reducing the proportion of filamentous particles. We find that antibodies against neuraminidase and M2 also restrict viral egress and that inhibition by anti-neuraminidase mAbs is only partly attributable to a loss in enzymatic activity. In all cases, antigen crosslinking—either on the surface of the infected cell, between the viral and cell membrane, or both—plays a critical role in inhibition, and we are able to distinguish between these modes experimentally and through a structure-based computational model. Together, these results provide a framework for dissecting antibody multifunctionality that could help guide the development of improved therapeutic antibodies or vaccines and that can be extended to other viral families and antibody isotypes. IMPORTANCE Antibodies against influenza A virus provide multifaceted protection against infection. Although sensitive and quantitative assays are widely used to measure inhibition of viral attachment and entry, the ability of diverse antibodies to inhibit viral egress is less clear. We address this challenge by developing an imaging-based approach to measure antibody inhibition of virus release across a panel of monoclonal antibodies targeting the influenza A virus surface proteins. Using this approach, we find that inhibition of viral egress is common and can have similar potency to the ability of an antibody to inhibit viral entry. Insights into this understudied aspect of antibody function may help guide the development of improved countermeasures.

Antibody-dependent enhancement of influenza disease promoted by increase in hemagglutinin stem flexibility and virus fusion kinetics

Influenza A Virus Antibodies with Antibody-Dependent Cellular Cytotoxicity Function

Fcγ Receptors Contribute to the Antiviral Properties of Influenza Virus Neuraminidase-Specific Antibodies

Free-energy Simulations Reveal That Both Hydrophobic and Polar Interactions Are Important for Influenza Hemagglutinin Antibody Binding.

Influenza virus antibodies inhibit antigen-specific de novo B cell responses in mice

Fc-Effector-Independent in vivo Activity of a Potent Influenza B Neuraminidase Broadly Neutralizing Antibody

The Human Antibody Response to the Influenza Virus Neuraminidase Following Infection or Vaccination

Structural Convergence and Water-Mediated Substrate Mimicry Enable Broad Neuraminidase Inhibition by Human Antibodies

A small-molecule fusion inhibitor of influenza virus is orally active in mice

Preconfiguration of the antigen-binding site during affinity maturation of a broadly neutralizing influenza virus antibody

Molecular Mechanism for Antibody-Dependent Enhancement of Coronavirus Entry

Broadly protective bispecific antibodies that simultaneously target influenza virus hemagglutinin and neuraminidase

Characterization of non-neutralizing human monoclonal antibodies that target the M1 and NP of influenza A viruses

Fc-dependent protective efficacy of non-inhibitory antibodies targeting influenza A virus neuraminidase is limited by epitope availability

How innate immune mechanisms contribute to antibody-enhanced viral infections

Universal antibody targeting the highly conserved fusion peptide provides cross-protection in mice

Structure-Based Modification of an Anti-neuraminidase Human Antibody Restores Protection Efficacy against the Drifted Influenza Virus

Antibody inhibition of influenza A virus assembly and release

Nanoparticle display of neuraminidase elicits enhanced antibody responses and protection against influenza A virus challenge

Antigen modifications improve nucleoside-modified mRNA-based influenza virus vaccines in mice

Neutralizing antibodies from the rare convalescent donors elicited antibody-dependent enhancement of SARS-CoV-2 variants infection